




Complete if Known

Application Number	09/078,917 09/997,623
Filing Date	October 17, 2001 Nov. 29, 2001
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1744 1646 1653
Examiner Name	Unassigned
Attorney Docket Number	0210,310US 0219US410

(use as many sheets as necessary)

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilbør Andersen
	Group Art Unit	1744 1683
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
CHK	23	EP	0 370 205	A2	Kyowa Hokko Kogyo Co., LTD.	05/30/1990		
	24	EP	0 575 054	A2	Eli Lilly and Company	12/22/1993		
	25	JP	3072877		Teijin LTD.	03/28/1991		X
	26	JP	08-092294		Teijin LTD. (ABSTRACT ONLY)	09/04/1996		X
	27	WO	89/05824	A1	Genetics Institute, Inc.	06/29/1989		
	28	WO	98/44000	A1	T.A.C. Thrombosis and Coagulation Aktiebolag	10/08/1998		
	29	WO	99/20767	A1	Regents of the University of Minnesota	04/29/1999		
	30	WO	00/26230	A1	Novo Nordisk	05/11/2000		
	31	WO	00/26354	A1	Novo Nordisk	05/11/2000		
	32	WO	00/54787	A1	The Children's Hospital of Philadelphia	09/21/2000		
	33	WO	00/66753	A2	Regents of the University of Minnesota	11/09/2000		
	34	WO	0066754	A1	Eli Lilly and Company	11/09/2000		
	35	WO	01/36463	A2	Eli Lilly and Company	05/25/2001		
	36	WO	01/57193	A2	Eli Lilly and Company	08/09/2001		
CHK	37	WO	01/59084	A1	Eli Lilly and Company	08/16/2001		
Examiner Signature		CBL / [Signature]				Date Considered	6/22/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/P INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilbourn Andersen
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
CMK	38	COLPITTS, TRACEY L. et al., "Binding of Calcium to Individual γ -Carboxyglutamic Acid Residues of Human Protein C", <i>Biochemistry</i> , 1995, 34, 2424-2430	
	39	FRIEDRICH, UTE. et al., "Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va", <i>The Journal of Biological Chemistry</i> , 2001, Vol. 276, No. 25:23105-23108	
	40	FRIEDRICH, UTE et al., "Structural and Energetic Characteristics of the Heparin-binding Site in Antithrombotic Protein C", <i>The Journal of Biological Chemistry</i> , 2001, Vol. 276, No. 26:24122-24128	
	41	GALE, ANDREW J. et al., "The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites", <i>Blood</i> , 2000, Vol. 96, No. 2:585-593	
	42	GALE, ANDREW J. et al., "Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va" <i>Protein Science</i> , (1997), 6:132-140	
	43	GENG, JIE-PING et al., "Functional Consequences of Mutations in Amino Acid Residues that Stabilize Calcium Binding to the First Epidermal Growth Factor Homology Domain of Human Protein C", <i>Thrombosis and Haemostasis</i> , (1990) 76:720-728	
	44	GERLITZ, BRUCE et al., "Mutation of Protease Domain Residues Lys37-39 in Human Protein C Inhibits Activation by the Thrombomodulin-Thrombin Complex without Affecting Activation by Free Thrombin", <i>The Journal of Biological Chemistry</i> , 1996, Vol. 271, No. 37:22285-22288	
	45	HALLAM, PAULA J. et al., "A novel missense mutation (Thr176→Ile) at the putative hinge of the neo N-terminus of activated protein C", <i>Hum Genet</i> , (1995) 95:447-450	
	46	HOLLY, RICK D. et al., "Resistance to inhibition by α -1Anti-Trypsin and Species Specificity of a Chimeric Human/Bovine Protein C", <i>Biochemistry</i> , (1994) 33:1876-1880	
	47	JHINGAN, ASHISH et al., "The Activities of Recombinant γ -Carboxyglutamic-Acid-Deficient Mutants of Activated Human Protein C toward Human Coagulation Factor Va and Factor VIII in Purified Systems and in Plasma", <i>Biochemistry</i> , (1994) 33:1869-1875	
	48	MCDONALD, JOHN F. et al., "Comparison of Naturally Occurring Vitamin K-Dependent Proteins: Correlation of Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site", <i>Biochemistry</i> , (1997) 36:5120-5127	
CMK	49	MESTERS, ROLF M. et al., "A Novel Exosite in the Light Chain of Human Activated Protein C Essential for Interaction with Blood Coagulation Factor Va", <i>Biochemistry</i> , (1993) 32:12656-12663	

Examiner Signature	<i>CMK</i>	Date Considered	6/22/04
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilb ur Andersen
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

CMK	50	MESTERS, ROLF M. et al., "Identification of a Sequence of Human Activated Protein C (Residues 390-404) Essential for Its Anticoagulant Activity", <i>The Journal of Biological Chemistry</i> , 1991, Vol.266, No. 36:24514-24519	
	51	NISHIOKA, JUNJI et al., "The Gla26 Residue of Protein C is Required for the Binding of Protein C to Thrombomodulin and Endothelial Cell Protein C Receptor, but not to Protein S and Factor Va", <i>Thrombosis and Haemostasis</i> , (1996) 75:275-282	
	52	ÖHLIN, ANN-KRISTIN et al., "Proteolytic Formation and Properties of a Fragment of Protein C Containing the γ -Carboxyglutamic Acid Rich Domain and the EGF-like Region", <i>Biochemistry</i> , (1990) 29:644-651	
	53	REZAIE, ALIREZA, R. "Role of Residue 99 at the S2 Subsite of Factor Xa and Activated Protein C in Enzyme Specificity", <i>The Journal of Biological Chemistry</i> , 1996, Vol. 271, No. 39:23807-23814	
	54	REZAIE, ALIREZA, R. "Calcium inhibition of the activation of protein C by thrombin Role of the P3 and P3' residues", <i>Eur. J. Biochem.</i> , (1994) 223:575-579	
	55	REZAIE, ALIREZA, R. "Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1", <i>The Journal of Biological Chemistry</i> , May 11, 2001, Vol. 276, No. 19:15567-15570	
	56	REZAIE, ALIREZA, R. et al., "Conversion of Glutamic Acid 192 to Glutamine in Activated Protein C Changes the Substrate Specificity and Increases Reactivity toward Macromolecular Inhibitors", <i>The Journal of Biological Chemistry</i> , 1993, Vol. 268, No. 27:19943-19948	
	57	RINTELEN, CLAUDIA et al., "Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation", <i>Thrombosis and Haemostasis</i> , (2001) 85:274-279	
	58	SHEN, LEI et al., "Enhancing the Activity of Protein C by Mutagenesis To Improve the Membrane-Binding Site: Studies Related to Proline-10", <i>Biochemistry</i> , 1997, Vol. 36, No. 51:16025-16031	
	59	SHEN, LEI et al., "Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ -Carboxyglutamic Acid Domain", <i>The Journal of Biological Chemistry</i> , 1998, Vol. 273, No. 47:31086-31091	
	60	SHEN, LEI et al., "Interspecies Loop Grafting in the Protease Domain of Human Protein C Yielding Enhanced Catalytic and Anticoagulant Activity", <i>Thrombosis and Haemostasis</i> , (1999) 82:1078-1087	
CMK	61	SHEN, LEI et al., "Tracking Structural Features Leading to Resistance of Activated Protein C to α 1-antitrypsin", <i>Biochemistry</i> , (2000) 39:2853-2860	

Examiner Signature		Date Considered	6/22/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilbourn Andersen
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

CMK	62	THARIATH, ABRAHAM et al., "Highly conserved residue arginine-15 is required for the Ca ²⁺ -dependent properties of the γ -carboxyglutamic acid domain of human anticoagulation Protein C and activated Protein C", <i>Biochem. J.</i> , (1997) 322:309-315	
	63	ZHANG, LI et al., "Role of Individual γ -Carboxyglutamic Acid Residues of Activated Human Protein C in Defining its In Vitro Anticoagulant Activity", <i>Blood</i> , 1992, Vol. 80, No. 4:942-952	
	64	ZHANG, LI et al., "The Binding Energy of Human Coagulation Protein C to Acidic Phospholipid Vesicles Contains a Major Contribution from Leucine 5 in the γ -Carboxyglutamic Acid Domain", <i>The Journal of Biological Chemistry</i> , 1994, Vol. 269, No.5:3590-3595	
CMK	65	ZHANG, LI et al., "Role of the Hexapeptide Disulfide Loop Present in the γ -Carboxyglutamic Acid Domain of Human Protein C in Its Activation Properties and in the in Vitro Anticoagulant Activity of Activated Protein C", <i>Biochemistry</i> , (1991) 30:6696-6704	

Examiner Signature		Date Considered	6/22/04
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.